Dapagliflozin CKD Trial Stopped Early Due to “Overwhelming Efficacy”
The decision to stop the trial was made based on positive efficacy data following a recommendation from the study’s independent DMC.
Cardiovascular Disease
Concomitant Myocardial Injury With COVID-19 Infection Linked to Fatal Outcome
Elevated TnT levels associated with arrhythmias, use of glucocorticoid therapy, mechanical ventilation
Cardiac Injury Linked to Increased Mortality in COVID-19
More hospitalized patients with cardiac injury required noninvasive or invasive mechanical ventilation.
Update for SGLT2 Inhibitors: Temporary Discontinuation Prior to Surgery Recommended
The FDA has approved safety labeling changes for sodium glucose co-transporter-2 (SGLT2) inhibitors. These include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.
Statement Addresses Concerns About Heart Meds and COVID-19
Patients advised to continue ACE inhibitors/ARBs after researcher posits risk for severe COVID-19 infection.
FDA Issues Statement Regarding NSAID Use and COVID-19
The FDA has issued a statement regarding the use of nonsteroidal anti-inflammatory drugs (NSAIDS) in patients with coronavirus disease 2019 (COVID-19).
Empagliflozin Fast-Tracked for Chronic Kidney Disease Treatment
The FDA has granted Fast Track designation for empagliflozin (Jardiance; Boehringer Ingelheim and Lilly) to reduce the risk of kidney disease progression and cardiovascular (CV) death in adults with chronic kidney disease.
Americans’ Protein-Rich Diets May Up Heart Disease Risk
Findings may have important public health implications for chronic disease prevention.
Combo Therapy Nexlizet Approved for Lowering LDL-C
Nexlizet will be available as 180mg bempedoic acid/10mg ezetimibe tablets in 30- and 90-count bottles in July 2020; Nexletol will be available on March 30, 2020.
Apabetalone Gets Breakthrough Tx Designation for MACE Prevention
The FDA has granted Breakthrough Therapy designation to apabetalone (Resverlogix Corp) in combination with standard of care therapy, including high-intensity statins, for the secondary prevention of major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus and recent acute coronary syndrome.
Next post in Cardiovascular Disease (CVD)
